04-15-2021, 09:25 PM
There was a study comparing Ivermectin and HCQ treatments (quote taken from https://covid19criticalcare.com/wp-conte...VID-19.pdf):
"The largest RCT (random controlled trial) in hospitalized patients was performed concurrent with the prophylaxis study
reviewed above by Elgazzar et al (Elgazzar et al., 2020). 400 patients were randomized amongst 4
treatment groups of 100 patients each. Groups 1 and 2 included mild/moderate illness patients only,
with Group 1 treated with one dose 0.4mg/kg ivermectin plus standard of care (SOC) and Group 2
received hydroxychloroquine (HCQ) 400mg twice on day 1 then 200mg twice daily for 5 days plus
standard of care. There was a statistically significant lower rate of progression in the ivermectin
treated group (1% vs. 22%, p<.001) with no deaths and 4 deaths respectively.
Groups 3 and 4 all included only severely ill patients, with group 3 again treated with single dose of 0.4mg/kg plus SOC
while Group 4 received HCQ plus SOC. In this severely ill subgroup, the differences in outcomes
were even larger, with lower rates of progression 4% vs. 30%, and mortality 2% vs 20% (p<.001). "
"The largest RCT (random controlled trial) in hospitalized patients was performed concurrent with the prophylaxis study
reviewed above by Elgazzar et al (Elgazzar et al., 2020). 400 patients were randomized amongst 4
treatment groups of 100 patients each. Groups 1 and 2 included mild/moderate illness patients only,
with Group 1 treated with one dose 0.4mg/kg ivermectin plus standard of care (SOC) and Group 2
received hydroxychloroquine (HCQ) 400mg twice on day 1 then 200mg twice daily for 5 days plus
standard of care. There was a statistically significant lower rate of progression in the ivermectin
treated group (1% vs. 22%, p<.001) with no deaths and 4 deaths respectively.
Groups 3 and 4 all included only severely ill patients, with group 3 again treated with single dose of 0.4mg/kg plus SOC
while Group 4 received HCQ plus SOC. In this severely ill subgroup, the differences in outcomes
were even larger, with lower rates of progression 4% vs. 30%, and mortality 2% vs 20% (p<.001). "